SpyGlass Pharma strengthens its supply chain by acquiring AVS from Santen Pharmaceutical for $13 million, securing essential manufacturing capacity for its Phase 3 BIM-IOL clinical trials.
SpyGlass Pharma has acquired Advanced Vision Science (AVS) for $13 million in cash to internalize its supply chain for intraocular lenses. By securing AVS, which currently supplies the IOLs used in SpyGlass's two ongoing Phase 3 registrational trials for the BIM-IOL System, the company mitigates supply chain risks and gains the scalable manufacturing capacity necessary for future commercialization.
SpyGlass Pharma acquired AVS for approximately $13 million in cash.
AVS is the current supplier of the IOLs used in SpyGlass Pharma's two Phase 3 registrational trials for the BIM-IOL System.
Advanced Vision Science is acquired by SpyGlass Pharma, becoming part of SpyGlass's IOL supply chain; no public market impact.
Santen divests its wholly owned subsidiary AVS for $13 million, a small transaction that may streamline its ophthalmic device portfolio but has limited financial impact.
SpyGlass Pharma has acquired Advanced Vision Science (AVS) from Santen Pharmaceutical for $13 million in cash. The deal secures critical, scalable manufacturing capacity for the company's intraocular lenses, directly supporting its ongoing Phase 3 registrational trials for the BIM-IOL System.
The acquisition provides SpyGlass Pharma with scalable commercial manufacturing capacity for its intraocular lenses, which are currently being evaluated in Phase 3 clinical trials.
Santen Pharmaceutical divested its wholly owned subsidiary for $13 million, a transaction that has limited financial impact but helps the company streamline its ophthalmic device operations.